Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SIRT2 | Q8IXJ6 | 1/20 | 0.43 |
| ▸ | CARM1 | Q86X55 | 1/20 | 0.43 |
| ▸ | PRMT6 | Q96LA8 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19291575 | 1.00 | SIRT2 (0.43) | SIRT2CARM1PRMT6 | |
| SCHEMBL19291875 | 1.00 | SIRT2 (0.43) | SIRT2CARM1PRMT6 | |
| SCHEMBL25819681 | 1.00 | SIRT2 (0.43) | SIRT2CARM1PRMT6 | |
| SCHEMBL19291555 | 1.00 | SIRT2 (0.43) | SIRT2CARM1PRMT6 | |
| SCHEMBL19291785 | 0.99 | CARM1 (0.43) | CARM1PRMT6 | |
| SCHEMBL19291653 | 0.99 | CARM1 (0.43) | CARM1PRMT6 | |
| SCHEMBL25819616 | 0.96 | CARM1 (0.43) | CARM1PRMT6 | |
| SCHEMBL22700926 | 0.94 | SIRT2 (0.42) | SIRT2CARM1PRMT6 | |
| SCHEMBL16030334 | 0.88 | CARM1 (0.41) | CARM1PRMT6 | |
| SCHEMBL19291674 | 0.88 | ACACA (0.42) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 64 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12029708-B2 | Alkoxy compounds for disease treatment | ACUCELA INC. (US) | 2024-07-09 | — | — | US | disclosed |
| US-12029708-B2 | Alkoxy compounds for disease treatment | ACUCELA INC. (US) | 2024-07-09 | — | — | US | disclosed |
| US-12029708-B2 | Alkoxy compounds for disease treatment | ACUCELA INC. (US) | 2024-07-09 | — | — | US | disclosed |
| US-11795136-B2 | Methods for the treatment of diabetic retinopathy and other ophthalmic diseases | ACUCELA INC. (US) | 2023-10-24 | — | — | US | disclosed |
| US-20230218549-A1 | ALKOXY COMPOUNDS FOR DISEASE TREATMENT | ACUCELA INC. | 2023-07-13 | — | — | US | disclosed |
| US-20230218549-A1 | ALKOXY COMPOUNDS FOR DISEASE TREATMENT | ACUCELA INC. | 2023-07-13 | — | — | US | disclosed |
| US-20230218549-A1 | ALKOXY COMPOUNDS FOR DISEASE TREATMENT | ACUCELA INC. | 2023-07-13 | — | — | US | disclosed |
| US-11446261-B2 | Alkoxy compounds for disease treatment | ACUCELA INC. (US) | 2022-09-20 | — | — | US | disclosed |
| US-20210171435-A1 | Methods for the Treatment of Diabetic Retinopathy and other Ophthalmic Diseases | ACUCELA INC. | 2021-06-10 | — | — | US | disclosed |
| US-20210077427-A1 | ALKOXY COMPOUNDS FOR DISEASE TREATMENT | ACUCELA INC. | 2021-03-18 | — | — | US | disclosed |
| US-20120129894-A1 | Alkoxy Compounds for Disease Treatment | ACUCELA INC. (US) | 2012-05-24 | — | — | US | disclosed |
| US-20120122938-A1 | Alkoxy Compounds for Disease Treatment | ACUCELA INC. (US) | 2012-05-17 | — | — | US | disclosed |
| US-20120122938-A1 | Alkoxy Compounds for Disease Treatment | ACUCELA INC. (US) | 2012-05-17 | — | — | US | disclosed |
| US-7982071-B2 | Alkoxy compounds for disease treatment | ACUCELA INC. (US) | 2011-07-19 | — | — | US | disclosed |
| US-7982071-B2 | Alkoxy compounds for disease treatment | ACUCELA INC. (US) | 2011-07-19 | — | — | US | disclosed |
| US-7982071-B2 | Alkoxy compounds for disease treatment | ACUCELA INC. (US) | 2011-07-19 | — | — | US | disclosed |
| US-20090326074-A1 | Alkoxy compounds for disease treatment | ACUCELA INC. (US) | 2009-12-31 | — | — | US | disclosed |
| US-20090326074-A1 | Alkoxy compounds for disease treatment | ACUCELA INC. (US) | 2009-12-31 | — | — | US | disclosed |
| US-20090326074-A1 | Alkoxy compounds for disease treatment | ACUCELA INC. (US) | 2009-12-31 | — | — | US | disclosed |
| WO-2009045479-A1 | ALKOXY COMPOUNDS FOR DISEASE TREATMENT | ACUCELA INC. (US) | 2009-04-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12029708-B2 | Alkoxy compounds for disease treatment | ALDH1A2, CLN6, AGER | SIRT2 923/4885CARM1 3417/4885PRMT6 3602/4885 |
| US-20120122938-A1 | Alkoxy Compounds for Disease Treatment | ALDH1A2, CLN6, AGER | SIRT2 923/4885CARM1 3417/4885PRMT6 3602/4885 |
| US-20210077427-A1 | ALKOXY COMPOUNDS FOR DISEASE TREATMENT | ALDH1A2, CLN6, AGER | SIRT2 923/4885CARM1 3417/4885PRMT6 3602/4885 |
| US-20230218549-A1 | ALKOXY COMPOUNDS FOR DISEASE TREATMENT | ALDH1A2, CLN6, AGER | SIRT2 903/4885CARM1 3318/4885PRMT6 3578/4885 |
| US-11795136-B2 | Methods for the treatment of diabetic retinopathy and other ophthalmic diseases | ALDH1A2, ALDH1A3, RBP4 | SIRT2 826/4885CARM1 4075/4885PRMT6 2115/4885 |
| US-20210171435-A1 | Methods for the Treatment of Diabetic Retinopathy and other Ophthalmic Diseases | ALDH1A2, ALDH1A3, RBP4 | SIRT2 826/4885CARM1 4075/4885PRMT6 2115/4885 |
| US-11446261-B2 | Alkoxy compounds for disease treatment | ALDH1A2, CLN6, AGER | SIRT2 923/4885CARM1 3417/4885PRMT6 3602/4885 |
| US-20090326074-A1 | Alkoxy compounds for disease treatment | ALDH1A2, CLN6, AGER | SIRT2 923/4885CARM1 3417/4885PRMT6 3602/4885 |
| US-20120129894-A1 | Alkoxy Compounds for Disease Treatment | ALDH1A2, CLN6, AGER | SIRT2 923/4885CARM1 3417/4885PRMT6 3602/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.